[company_age]unknown[/company_age][employees]11-50 employees[/employees][funding]Series unknown[/funding][description]21st.BIO is a Danish biotechnology company that specializes in scaling up the production of sustainable food and materials using industrial biotechnology. They partner with innovators to develop and optimize production processes for new molecules, enabling them to bring their products to market faster and more cost-effectively. 21st.BIO's unique value proposition lies in their expertise in strain engineering, fermentation, and downstream processing, as well as their access to a world-class technology platform licensed from Novozymes. This allows them to offer a comprehensive solution that covers the entire development and manufacturing process, from initial strain construction to commercial-scale production. 21st.BIO's focus on sustainability sets them apart from competitors, as they are committed to using environmentally friendly processes and materials. They are also actively involved in collaborations with other companies, such as AMSilk, to develop and scale up the production of innovative biomaterials.[/description][ps]21st.BIO offers a range of services to help innovators develop and scale up the production of sustainable food and materials using industrial biotechnology. These services include:\n\n* Technical assessment and roadmap development\n* Strain engineering and optimization\n* Fermentation process development\n* Downstream processing development\n* Pilot-scale production\n* Technology transfer\n* Regulatory support[/ps]